Semaglutide access and health inequity

Semaglutide works for obesity, and that much is settled. What is not settled is who gets to take it, and a letter published in Postgraduate Medical Journal on 22 September 2026 makes exactly that its argument: the binding constraint on semaglutide is no longer whether the drug is effective, it is who can reach it^[1]. The World Health Organization had already said something similar. Its December 2025 guideline on GLP-1 therapies projects that, even with expanded manufacturing, these medicines will reach fewer than 10% of the people who could benefit by 2030^[2].

The efficacy case is largely closed

The trial record behind semaglutide is the strongest of any compound in our peptide library. The Postgraduate Medical Journal letter opens with the figures most clinicians now quote from memory: a mean body-weight reduction of 14.9% against 2.4% on placebo, plus a cardiovascular benefit in people with established heart disease^[1]. Global health policy has caught up with that evidence. WHO added semaglutide to its Model List of Essential Medicines in September 2025, alongside dulaglutide, liraglutide and tirzepatide^[3]. The listed indication is narrower than the public conversation suggests: adults with type 2 diabetes who also have established cardiovascular disease or chronic kidney disease and obesity at a BMI of 30 or above^[3].

Insurance is not the finish line

A cohort study published in JAMA Health Forum in October 2025 followed 9,848 GLP-1 receptor agonist orders written for 6,094 insured patients and asked a narrow question: did the prescription get filled? Within 90 days, 60.1% did^[4]. Split the same orders by indication and a gap opens. Where the indication covered both diabetes and obesity, 64.6% were filled. Diabetes alone dropped that to 47.5%, and obesity on its own to 37.2%^[4]. Out-of-pocket cost tracked the same split, at a mean of $70.32 per 30-day supply where the indication included diabetes against $134.04 where it was obesity alone^[4].

Every patient in that analysis had insurance. The barrier showed up anyway, and it showed up unevenly: 60.9% of orders were filled for non-Hispanic White patients, 58.4% for Hispanic patients and 55.3% for non-Hispanic Black patients^[4]. A 2026 review of primary-care readiness describes the same pattern across the wider literature, reporting that minority ethnic groups, low-income communities and publicly insured patients are all less likely to receive or fill a GLP-1 prescription despite carrying more obesity-related disease^[5].

Rationing happens by system design too

Price is the obvious lever. It is not the only one. In England, NICE recommends semaglutide for weight management only inside a specialist weight management service, for a maximum of two years, and only for adults with at least one weight-related comorbidity plus a BMI of 35 or above, or a BMI of 30 to 34.9 for those who meet the referral criteria for specialist services^[6]. That is a defensible reading of where the trial evidence was generated. It is also a rationing mechanism, because eligibility then depends on securing a referral rather than on meeting the BMI threshold. NICE does correct one known inequity head-on, instructing clinicians to use BMI thresholds usually 2.5 kg/m2 lower for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds^[6]. Where the licensed route narrows, the unlicensed one tends to widen, which is the part of this story that surfaces on our semaglutide regulation page.

The global gap is the larger one

WHO's own framing is blunt. Announcing the essential-medicines update, the agency stated that "high prices of medicines like semaglutide and tirzepatide are limiting access to these medicines", and pointed to generic competition and delivery through primary care as two of the routes out^[3]. Three months later it issued a conditional recommendation that GLP-1 therapies may be used by adults, excluding pregnant women, for the long-term treatment of obesity. The conditionality is the point. WHO attached it to limited long-term data, current costs, inadequate health-system preparedness and potential equity implications, and warned that "without deliberate policies, access to these therapies could exacerbate existing health disparities"^[2]. Tirzepatide sits in the same bind, with the same pricing problem and the same country-by-country licensing patchwork.

What this means if you are trying to get treated

Knowing that the barrier is structural does not make it personal failure, and it does change what is worth asking. Whether your prescription is written for diabetes as well as obesity materially changes the odds it gets covered, so that is a conversation to have with a prescribing clinician rather than a detail to discover at the pharmacy counter^[4]. In the UK, the route into treatment usually runs through a specialist weight management service, which means the referral matters as much as the eligibility criteria^[6]. Our semaglutide page sets out the trial evidence and the regulatory position in each country we cover. None of it replaces a clinician who knows your history.

What we don't yet know

The piece that prompted this article is a letter to the editor, not original research^[1]. It frames a problem the data elsewhere supports; it does not add new measurements. The JAMA Health Forum cohort has a sharper limitation worth sitting with: mean out-of-pocket cost was actually lowest for non-Hispanic Black patients, at $41.15 per 30-day supply, yet their fill rate was the lowest of the three groups reported^[4]. Price alone does not explain that. Pharmacy access, prior-authorisation friction, trust in the prescriber and supply distribution are all candidates, and the cohort was not built to separate them. Nobody has yet published a good estimate of how much of the global gap closes when semaglutide loses patent protection in individual markets. This article is for educational and journalistic purposes only and does not constitute medical advice. Talk to a qualified healthcare professional before starting, stopping or changing any treatment.